Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
General Outlook
In simple terms, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. has 3424.51 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.927% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.227%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.207%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust 0.064% return, is a testament to Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s adeptness in optimizing resource deployment. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.085%. Furthermore, the proficiency of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. in capital utilization is underscored by a remarkable 0.091% return on capital employed.
Stock Prices
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.54, while its low point bottomed out at $2.47. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”